UA108346C2 - Спосіб модулювання антагоністичної активності моноклонального антитіла - Google Patents

Спосіб модулювання антагоністичної активності моноклонального антитіла

Info

Publication number
UA108346C2
UA108346C2 UAA201108283A UAA201108283A UA108346C2 UA 108346 C2 UA108346 C2 UA 108346C2 UA A201108283 A UAA201108283 A UA A201108283A UA A201108283 A UAA201108283 A UA A201108283A UA 108346 C2 UA108346 C2 UA 108346C2
Authority
UA
Ukraine
Prior art keywords
seq
hinge region
amino acid
antagonistic activity
modulation
Prior art date
Application number
UAA201108283A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/066205 external-priority patent/WO2010063746A1/en
Publication of UA108346C2 publication Critical patent/UA108346C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
UAA201108283A 2008-12-02 2009-02-12 Спосіб модулювання антагоністичної активності моноклонального антитіла UA108346C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055664 WO2010064090A1 (en) 2008-12-02 2008-12-02 Process for the modulation of the antagonistic activity of a monoclonal antibody
PCT/EP2009/066205 WO2010063746A1 (en) 2008-12-02 2009-12-02 Process for the modulation of the antagonistic activity of a monoclonal antibody

Publications (1)

Publication Number Publication Date
UA108346C2 true UA108346C2 (uk) 2015-04-27

Family

ID=40875011

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201108283A UA108346C2 (uk) 2008-12-02 2009-02-12 Спосіб модулювання антагоністичної активності моноклонального антитіла

Country Status (2)

Country Link
UA (1) UA108346C2 (ru)
WO (1) WO2010064090A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2481752B1 (en) * 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004309275B2 (en) * 2003-12-25 2010-12-23 Kyowa Kirin Co., Ltd. Mutants of anti-CD40 antibody
JP5142998B2 (ja) * 2005-07-18 2013-02-13 アムジエン・インコーポレーテツド ヒト抗ｂ７ｒｐ１中和抗体
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
EP2004693B1 (en) * 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met

Also Published As

Publication number Publication date
WO2010064090A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
UA108346C2 (uk) Спосіб модулювання антагоністичної активності моноклонального антитіла
TN2011000253A1 (en) Process for the modulation of the antagonistic activity of a monoclonal antibody
NZ591471A (en) Antibodies to ccr2
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
PH12014501872A1 (en) P-cadherin antibodies
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
WO2008124083A3 (en) Aurora kinase modulators and method of use
TW200724548A (en) Antibodies to myostatin
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
GEP20135917B (en) Stabilized polypeptide compositions
NO20082167L (no) Anti-Myostatin-antistoffer
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EA200970515A1 (ru) МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ
IN2010KN00318A (ru)
NZ598770A (en) Monoclonal antibodies
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2012018767A3 (en) Antibodies directed against il-17
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2006132739A3 (en) Novel chemical compounds
NZ774126A (en) Spd-1 variant - fc fusion proteins
ES2570182T3 (es) Prevención y tratamiento de la enfermedad sinucleinopática y amiloidogénica
DK2229946T3 (da) Anvendelse af vækst-stimulerende protein KIAA1524